CO2022003053A2 - Proteínas de unión a antígenos - Google Patents
Proteínas de unión a antígenosInfo
- Publication number
- CO2022003053A2 CO2022003053A2 CONC2022/0003053A CO2022003053A CO2022003053A2 CO 2022003053 A2 CO2022003053 A2 CO 2022003053A2 CO 2022003053 A CO2022003053 A CO 2022003053A CO 2022003053 A2 CO2022003053 A2 CO 2022003053A2
- Authority
- CO
- Colombia
- Prior art keywords
- antigen binding
- binding proteins
- compositions
- treatment
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962906876P | 2019-09-27 | 2019-09-27 | |
| US202063057508P | 2020-07-28 | 2020-07-28 | |
| PCT/EP2020/076834 WO2021058711A2 (en) | 2019-09-27 | 2020-09-25 | Antigen binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022003053A2 true CO2022003053A2 (es) | 2022-04-19 |
Family
ID=72840475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0003053A CO2022003053A2 (es) | 2019-09-27 | 2022-03-16 | Proteínas de unión a antígenos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11479607B2 (https=) |
| EP (1) | EP4034562B1 (https=) |
| JP (3) | JP7280387B2 (https=) |
| KR (1) | KR20220070011A (https=) |
| CN (2) | CN114729049B (https=) |
| AU (1) | AU2020355614B2 (https=) |
| BR (1) | BR112022005787A2 (https=) |
| CA (1) | CA3155173A1 (https=) |
| CO (1) | CO2022003053A2 (https=) |
| ES (1) | ES3053994T3 (https=) |
| IL (1) | IL291364A (https=) |
| MX (1) | MX2022003523A (https=) |
| MY (1) | MY207830A (https=) |
| PH (1) | PH12022550671A1 (https=) |
| TW (1) | TWI865617B (https=) |
| WO (1) | WO2021058711A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021058711A2 (en) | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| EP4540284A2 (en) | 2022-06-17 | 2025-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind interleukin 13 and methods of use |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| HU230847B1 (en) | 2000-05-19 | 2018-08-28 | Corixa Corp | Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds |
| CA2417806C (en) | 2000-08-04 | 2011-05-10 | Corixa Corporation | New immunoeffector compounds |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2008073316A2 (en) | 2006-12-07 | 2008-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| AU2008247382B2 (en) | 2007-05-07 | 2014-06-05 | Medimmune, Llc | Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| SG10202112838YA (en) | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| CA2809089C (en) | 2010-08-23 | 2018-12-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| EP3147297B1 (en) | 2011-03-31 | 2018-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| CA2845810C (en) | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| HK1210964A1 (en) | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| BR112016000853A2 (pt) | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| KR20250024106A (ko) * | 2013-08-22 | 2025-02-18 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절 |
| AU2013398294A1 (en) * | 2013-08-22 | 2016-03-17 | The Council Of The Queensland Institute Of Medical Research | Immunoreceptor modulation for treating cancer and viral infections |
| MD4733C1 (ro) * | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anticorpi anti-TIGIT |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| CA3048907C (en) * | 2017-01-06 | 2023-05-23 | Nantkwest, Inc. | Genetically modified nk-92 cells with decreased cd96/tigit expression |
| KR20200073203A (ko) * | 2017-08-11 | 2020-06-23 | 블링크 바이오메디컬 에스아에스 | 면역조절인자로서의 ｃｄ96-결합제 |
| CN110914304B (zh) | 2017-11-10 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | Cd96抗体、其抗原结合片段及医药用途 |
| TWI877769B (zh) * | 2017-12-30 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| TW202122420A (zh) | 2019-08-30 | 2021-06-16 | 美商艾吉納斯公司 | 抗ｃｄ９６抗體及其使用方法 |
| WO2021058711A2 (en) * | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
-
2020
- 2020-09-25 WO PCT/EP2020/076834 patent/WO2021058711A2/en not_active Ceased
- 2020-09-25 EP EP20789858.6A patent/EP4034562B1/en active Active
- 2020-09-25 KR KR1020227014021A patent/KR20220070011A/ko not_active Withdrawn
- 2020-09-25 CN CN202080080763.5A patent/CN114729049B/zh active Active
- 2020-09-25 MY MYPI2022001598A patent/MY207830A/en unknown
- 2020-09-25 ES ES20789858T patent/ES3053994T3/es active Active
- 2020-09-25 AU AU2020355614A patent/AU2020355614B2/en not_active Ceased
- 2020-09-25 BR BR112022005787A patent/BR112022005787A2/pt unknown
- 2020-09-25 MX MX2022003523A patent/MX2022003523A/es unknown
- 2020-09-25 JP JP2021571490A patent/JP7280387B2/ja active Active
- 2020-09-25 CN CN202411387665.2A patent/CN119431581A/zh active Pending
- 2020-09-25 PH PH1/2022/550671A patent/PH12022550671A1/en unknown
- 2020-09-25 TW TW109133431A patent/TWI865617B/zh active
- 2020-09-25 CA CA3155173A patent/CA3155173A1/en active Pending
-
2021
- 2021-11-19 US US17/530,849 patent/US11479607B2/en active Active
-
2022
- 2022-03-14 IL IL291364A patent/IL291364A/en unknown
- 2022-03-16 CO CONC2022/0003053A patent/CO2022003053A2/es unknown
- 2022-09-02 US US17/902,305 patent/US12528864B2/en active Active
-
2023
- 2023-05-10 JP JP2023078141A patent/JP7546723B2/ja active Active
-
2024
- 2024-08-20 JP JP2024139180A patent/JP2024167261A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023103352A (ja) | 2023-07-26 |
| CN114729049B (zh) | 2024-10-25 |
| CN119431581A (zh) | 2025-02-14 |
| IL291364A (en) | 2022-05-01 |
| JP7546723B2 (ja) | 2024-09-06 |
| JP7280387B2 (ja) | 2023-05-23 |
| TWI865617B (zh) | 2024-12-11 |
| AU2020355614A1 (en) | 2022-04-14 |
| MY207830A (en) | 2025-03-21 |
| US12528864B2 (en) | 2026-01-20 |
| JP2024167261A (ja) | 2024-12-03 |
| CN114729049A (zh) | 2022-07-08 |
| BR112022005787A2 (pt) | 2022-06-21 |
| US20230279106A1 (en) | 2023-09-07 |
| AU2020355614B2 (en) | 2024-12-05 |
| WO2021058711A2 (en) | 2021-04-01 |
| PH12022550671A1 (en) | 2023-05-29 |
| EP4034562A2 (en) | 2022-08-03 |
| KR20220070011A (ko) | 2022-05-27 |
| EP4034562C0 (en) | 2025-10-29 |
| CA3155173A1 (en) | 2021-04-01 |
| US20220089728A1 (en) | 2022-03-24 |
| US11479607B2 (en) | 2022-10-25 |
| WO2021058711A3 (en) | 2021-06-03 |
| MX2022003523A (es) | 2022-04-25 |
| ES3053994T3 (en) | 2026-01-28 |
| TW202128755A (zh) | 2021-08-01 |
| EP4034562B1 (en) | 2025-10-29 |
| JP2022535034A (ja) | 2022-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024236A2 (pt) | Proteínas multiespecíficas | |
| PE20210288A1 (es) | Anti-cd25 para el agotamiento de celulas tumorales especificas | |
| MX2017006167A (es) | Compuestos que interactúan con glicanos y métodos de uso. | |
| BR112021021230A8 (pt) | Forma de cristal de composto inibidor de wee1 e uso do mesmo | |
| CO2017011484A2 (es) | Inhibidores de bromodominio | |
| PE20201419A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| CO2019014286A2 (es) | Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas | |
| BR112018074453A2 (pt) | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral | |
| PE20161390A1 (es) | Anticuerpos multiespecificos | |
| MX391171B (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| AR114565A1 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
| MX2020005555A (es) | Construcciones inmunogenicas de peptidos de tau. | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| CL2021001615A1 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
| MX2021002292A (es) | Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa. | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| AR117327A1 (es) | Anticuerpos anti-cd96 y métodos de uso de estos | |
| CO2022003053A2 (es) | Proteínas de unión a antígenos | |
| EA202191403A1 (ru) | Композиция с высокой концентрацией белка | |
| MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
| CO2021003136A2 (es) | Terapias de combinación |